In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California Institute of Technology

https://www.caltech.edu/

Latest From California Institute of Technology

Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors

Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round. 

Finance Watch Financing

Westlake Village BioPartners Closes Two VC Funds Totaling $500m

A $70m fund will back prior investments, while a $430m fund will launch new biotech firms. Harper and Seidenberg tapped into their Amgen connections for the CEO who helms new company Acelyrin.

Financing Innovation

Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m

Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals... 

Deals Financing

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.

Research & Development Deals
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register